Try our Advanced Search for more refined results
Life Sciences - January, 2014
320 articles
- Edison Inks Potential $4.3B R&D Deal With Japan Pharma Co.
- FDA Probes Testosterone Products For Fatal Risks
- FTC Clears Thermo Fisher's $14B Life Tech Buy With GE Deal
- Precision BioSciences, Cellectis Settle Longtime Patent Feud
- Device Co. Pleads Guilty To Hiding Toxicity Data From FDA
- Rotech Judge Slashes Baker & McKenzie Fee Request
- Sandoz Asks High Court To Toss Fed. Circ. Allergan Ruling
- Abbott Can't Escape FCA Suit Over Drug Marketing, Kickbacks
- FTC New Year's Resolution: End Deceptive Weight-Loss Ads
- Novartis Sues Noven Over Generic Dementia Patch
- Endo Must Shed Drugs For $225M Boca Buy, FTC Says
- Female Powerbrokers Q&A: McAndrews' Sharon Hwang
- Female Powerbrokers Q&A: Faegre Baker's Kathy Noecker
- 'Reasonable Certainty' Remains Uncertain
- Class Cert. Denied In Pfizer Pay-For-Delay Suit
- Judge Nixes Remand Bid In J&J Infant's Tylenol Suit
- Waxman's Retirement Creates DC Policymaking Void
- Boehringer Docs In Pradaxa MDL Unsealed By Judge
- FDA Tells Consumers To Avoid 4 Weight-Loss Supplements
- Zimmer Accuses Stryker Of Plot To Poach Employees
- Plaintiffs Bar Targets Dietary Supplement Efficacy Claims
- Suit Over Costa Rican Probe Of Atty Can Stay In Fla.
- Drugmakers Defend No-Cash Patent Deals Post-Actavis
- Generics Lobby Floats Alternative To FDA Drug Labeling Plan
- Female Powerbrokers Q&A: Norton Rose's Yvonne Puig
- Female Powerbrokers Q&A: Orrick's Laurie Strauch Weiss
- Waxman, Longtime Leader In The House, To Retire
- Workplace Culture: The Real Pathway To Change
- Surgiview Says It's Not Liable For $37M Ex-Parent Owed
- Possible Sanctions For Takeda In Actos Bladder Cancer MDL
- Patheon Can't Shake Procaps Suit Over $255M Merger
- Star Scientific Action Halted As Feds Pursue Ex-Va. Gov.
- Martoma Witness Calls SAC's Cohen 'Greatest Trader' Ever
- Top DOJ Atty Outlines Pharma Fraud Enforcement
- Wilson Sonsini Reps Fluidigm In $207M DVS Sciences Deal
- Cipro Buyers, Generics Cos. Duel Over Actavis Ruling
- Eli Lilly Sues Par Pharma To Block Generic Effient
- Merz, Shionogi Shielded From Classen IP Suit, Judge Rules
- What Attorneys Should Know About FDA's MedWatch Data
- Google Wants Shareholder Suit Over $500M Ad Deal Nixed
- FDA Leaves Beverage-Labeling Questions Unanswered
- And Now A Word From The Panel: The Year In Review
- Female Powerbrokers Q&A: Goodwin Procter's Joanne Gray
- Female Powerbrokers Q&A: Taft's Barbara Duncombe
- Obama Asserts Executive Power In State Of The Union Speech
- 4th Circ. Tosses Generic-Drug Injury Appeal Against Pliva
- Arbitration Order Staying Suit Not Appealable, 9th Circ. Says
- Allergan Dodges Class Action Over Pricey Eye Drops
- $2.6M Olympus Shareholder Deal Gets Green Light
- J&J Beats $258M Risperdal Verdict In Split La. High Court
- Bankrupt MedLab To Sell Units To LabCorp For $10.5M
- Prosecution Rests In Martoma Insider Trading Case
- Merck, Bristol-Myers Settle With Generics Co. Over HIV Drug
- FTC Says Cephalon Put Ex-GC's Advice In Play
- Hydroxycut False Ad Claims Must Be Clarified, Judge Says
- FDA Wants To Review Drug Companies' Posts And Tweets
- Sarepta Accused Of Misleading Investors On MD Drug
- FDA Scolds Texas Drugmaker Over STD Product Promos
- GNC Hit With Suit Claiming Diet Pills Led To Liver Damage
- Mylan Generic Infringes Endo's Frova Patent, Judge Says
- Atty Fights Former Firm's Attempt To Arbitrate Fees Row
- Calif. Court Reverses Preemption Of Medtronic Injury Suit
- Female Powerbrokers Q&A: Young Conaway's Pauline Morgan
- Female Powerbrokers Q&A: Phelps Dunbar's Nan Alessandra
- J&J Beats $600M Stent Patent Verdict For Good
- Wash. Joins Suit Over Novartis Exjade Kickbacks
- Fla. Supreme Court OKs Medical Marijuana Ballot Initiative
- Eckert Seamans Adds Ex-Bayer General Counsel To PL Group
- Deals Rumor Mill: Carlyle, Vodafone, Altegrity
- DePuy Just Can't Shake Those Hip Replacement Lawsuits
- Loeb Adds Ex-Porzio Partner For New FDA Regulatory Practice
- J&J Urges FDA Deference In Baby Wash False Ad Action
- 3rd Circ. To Review Venue Ruling In GSK Birth Defects Case
- Female Powerbrokers Q&A: Crowell's Angela Styles
- Female Powerbrokers Q&A: WilmerHale's Susan Murley
- Actavis Only Requires Scrutiny Of Cash Deals, Judge Says
- 7th Circ. Reverses Boehringer Depo Order In Pradaxa MDL
- Cochlear Hit With $131M Verdict In Implant Patent Trial
- Steptoe & Johnson Opens Office In Palo Alto
- 5 Takeaways From FDA Overture On Generic-Drug Approvals
- Fed. Circ. Junks Patents On Treatment-Picking Program
- Covidien Wins Surgical Tool Patent Suit By J&J Unit
- Shuttered Debt Collector Withheld $90M, Quest Says
- What's In The Wash? FDA Rules On Antibacterial Soaps
- Clinics Ink $2M FCA Deal In Reimported Drugs Case
- 6th Circ. Won't Rehear Generic-Reglan Injury Claims
- Thoratec Hit With Shareholder Suit Over Device Recall, Study
- Teva, Boehringer Slapped With New Pay-For-Delay Suit
- St. Jude Can't Shake Defective Defibrillator Suits
- Female Powerbrokers Q&A: Hughes Hubbard's Beinecke
- Female Powerbrokers Q&A: Willkie's Margery Neale
- McKesson Salvages Celesio Buy With Reworked Deals
- Cephalon Says Patent Toss Doesn't Bar Pay-For-Delay Defense
- Cohen Real Target In Probe Of SAC's Martoma, Witness Says
- Another Ranbaxy Drug Plant Fails FDA Test
- GOP Lawmakers Rip FDA's Generic-Drug Labeling Overhaul
- Pa. Pharma Ruling Opens New Front In Mass Tort Battles
- Baxter Sues J&J For Violating Floseal Patents
- Medicare Billing Records Give FCA Whistleblowers New Ammo
- USPTO Says Group Lacks Standing In Stem Cell Patent Appeal
- Norton Rose Fulbright Draws In 2 Shook Hardy Health Pros
- Shire Doesn't Have To Return Docs In Generic Dispute
- FDA Analyzing Foods For Caramel Coloring Danger
- Philips Didn't Interfere With Worker's New Job, Judge Rules
- Eli Lilly Sues Glenmark Over Cancer Drug ANDA
- Mylan Sues Insys Over Attempt To Cut Off Distribution Deal
- Sen. Calls For Probe Into Herbalife Pyramid Scheme Claims
- Female Powerbrokers Q&A: Fluet Huber's Jennifer Huber
- Female Powerbrokers Q&A: Goldberg Segalla's Berdzik
- Alibaba, PE Partner Sink $171M Into Drug Data Venture
- Proposed FDA Rule Could Bring Failure-To-Warn Liability
- Ex-Prof. Says Martoma Ditched Him After Tips Led To Trades
- Justices' Burden-Of-Proof Ruling Gives Licensees A Leg Up
- EBay, PayPal Hit With Suit Over Prosthetics Listings
- FDA Updates Mad Cow Disease Guidance For Medical Devices
- Pfizer Escapes Whistleblower Suit Over Lipitor Marketing
- Cigna Coverage Row Shouldn't Be Arbitrated, 3rd Circ. Told
- Fed. Circ. Strikes Down Medtronic Heart Valve Patent
- FDA Overhauls 'Dear Doctor' Guidance On Drug Risks
- Nu Skin Hit With Investor Suit Over China Operations
- 23andMe Faces Suit Over Recently Banned DNA Tests
- Affymax Largely Ducks Investor Suit Over Anemia Drug
- Female Powerbrokers Q&A: Anderson Kill's Pamela Hans
- Pharma Can Be Liable For Design Negligence: Pa. High Court
- Female Powerbrokers Q&A: Cozen O'Connor's Mayes
- High Court Rules Patent Owners Have Burden Of Proof
- Quest Diagnostics Puts Up $570M For PE-Backed Lab Co.
- Reversal Over Sacked Gay Juror To Guide Jury Selection
- AstraZeneca Seeks Full Rehearing Of Generic Drugmaker Win
- Prof Says Ex-SAC Manager Got Details On Drug Study
- FDA Balks At Trial Design For Amarin's Fish Oil Drug
- Conflicts Doom Baker & McKenzie Fee Bid, Rotech Says
- Making Sense Of CLS Bank In View Of Prometheus, Alappat
- Gay Juror Wrongly Booted In GSK-Abbott Row, 9th Circ. Says
- Pa. Appeals Court Upholds Transfer Of Asbestos Cases
- Teva Asks Supreme Court To Weigh De Novo Review
- FDA Warns Medical Food Co. Amid Continuing Crackdown
- Spectranetics CEO Can't Shake False Statement Conviction
- Ted Kennedy Jr. Joins Epstein Becker Green's Health Group
- NAD Refers Salonpas Ad Claims To FDA, FTC
- Judge Not Racially Biased Against Investor, 2nd Circ. Says
- 6th Circ. Revives Mylan Wrongful Death Suit
- China Says IP Crackdown Led To 60K Arrests In 2013
- Female Powerbrokers Q&A: Alston & Bird's Nicki Carlsen
- Female Powerbrokers Q&A: Shackelford's Nicole LeBoeuf
- Elliott Ups Celesio Stake After Failed $8.5B McKesson Buy
- NuPathe Nixes Endo Deal, OKs $114M Teva Takeover
- Merck Gender Bias Suit Swells To $250M After Plaintiffs Added
- Jury Clears Abbott In Tainted Formula Injury Suit
- Professor Testifies He Tipped Ex-SAC Manager Martoma
- Device Cos. Get FDA Guidance On Computer Simulation
- Warner Chilcott Contraceptive Patent Upheld By Judge
- Drug Cos. Say Noerr Doctrine Bars FTC's Pay-For-Delay Suit
- Avanir Faces Investor Suit Over 'Tax Deductible' Claims
- Altaris Strikes $130M Deal To Buy Endo's HealthTronics
- Shire Sells Dermagraft To Organogenesis At $650M Loss
- Female Powerbrokers Q&A: Jackson Kelly's Ellen Cappellanti
- Female Powerbrokers Q&A: Cole Schotz's Randi Kochman
- 3 Cost-Cutting Resolutions Law Firms Can't Afford To Break
- After Dolly: The Status Of Nonhuman Clones In Patent Law
- Senate Sends $1T Federal Spending Bill To Obama's Desk
- Alvogen Set To Gain Majority Of Lotus In $200M Asset Swap
- Aegerion Hit With Shareholder Suit Over Juxtapid Labeling
- Gentium Investors Sue Over $1B Jazz Pharma Deal
- Iovate Stuck In Bodybuilding Supplement False Ad Suit
- Savient Hid Cash Woes Before Ch. 11 Sale, Investors Say
- Female Powerbrokers Q&A: Fox Rothschild's Resnick
- Female Powerbrokers Q&A: Roetzel's Erika Haupt
- Carlyle Puts Up $4B For J&J's Blood-Testing Unit
- China Conditionally OKs Thermo Fisher's $14B Life Tech Buy
- Clinical Labs Under ACA: Challenge And Opportunity
- 4 Lessons From FDA's Social Media Guidance
- Affymax Says It Didn't Mislead Investors About Anemia Drug
- Fed. Circ. Ruling Clears Way For Longer Patent Terms
- NuVasive Can't Dodge Orthopedic Patent Suit
- Ex-SAC Manager Had Early Read On Study, Court Hears
- Life Sciences Group Of The Year: WilmerHale
- Vitamin Shoppe Ducks Bodybuilding Supplement False Ad Suit
- House Passes $1T Federal Spending Bill
- Deals Rumor Mill: Time Warner, Carlyle, Aeropostale
- Jury Awards Edwards $393M In Medtronic Valve Patent Row
- Female Powerbrokers Q&A: Holland & Hart's Liz Sharrer
- Female Powerbrokers Q&A: Anderson Kill's Rhonda Orin
- McCarter & English Picks Up Porzio Product Liability Vet
- Facts Show Patent Trolls Not Behind Rise In Suits
- A Push By The USPTO For Faster Patent Processing
- Doctor Says He Tipped Former SAC Manager Martoma
- Allergan Stymies Generic Glaucoma Med In Patent Trial
- Merck Recalls Supply Of Cholesterol Drug Liptruzet
- Life Sciences Group Of The Year: White & Case
- Siemens Beats Whistleblower's FCA Suit Over VA Charges
- Teva Didn't Infringe OxyContin Patents, NY Judge Rules
- FDA Outlines New Stance On Patient-Specific Devices
- Deals Rumor Mill: Forbes, Pfizer, Bankia
- $1T Bill Ups Tech, Finance Budgets, Cuts ACA Funds
- Big Pharma's Pricing Power Imperiled By Part D Overhaul
- Roche Loses Last Shot At Booting NJ Accutane Judge
- AstraZeneca Can't Duck Pharmacies' Claims In Nexium MDL
- Female Powerbrokers Q&A: Debevoise's Mary Beth Hogan
- Female Powerbrokers Q&A: Sanford's Katherine Kimpel
- McKesson's $8.5B Bid for Celesio Falls Flat
- Ropes & Gray Reps Genzyme In $700M Deal For Alnylam Stake
- Pfizer Faces Whistleblower Suit Over Lipitor Marketing
- FDA Should Assume Authority Over Human Cloning
- Forest Can't Nix Mo. Class In Antidepressant Marketing MDL
- FDA Gives Drugmakers Taste Of Social Media Rules
- Life Sciences Group Of The Year: Paul Hastings
- NJ Court Orders Report On Medical Marijuana Program
- Jones Day Adds Food And Drug Partner From Akin Gump
- Female Powerbrokers Q&A: Otterbourg's Melanie Cyganowski
- Female Powerbrokers Q&A: Epstein Becker's Joan Disler
- FTC Dissent Could Spell End To Strict Health Ad Standard
- Ex-SAC Manager Martoma Sought 'Illegal Edge,' Jurors Hear
- (Foreign) Food For Thought: Risks From Chinese Imports
- Science Question Hangs Over High Court Birth Control Case
- Justices Take 2 Patent Cases On Inducement, Indefiniteness
- Life Sciences Group Of The Year: Kirkland & Ellis
- Mintz Levin Nabs Health Care FCA Pro From Patton Boggs
- FDA Pushes Hospitals To Buy From Registered Compounders
- Alcon Aims To Halt Micro Labs' Generic Glaucoma Drug
- Female Powerbrokers Q&A: Wilson Elser's Publicover
- Female Powerbrokers Q&A: Fowler White's Rhea Law
- Boston Scientific Loses Bid To Lift Ban On Catheter Sales
- Inequitable Conduct Won't Undo Attorney-Client Privilege
- 4th Circ. Leaves 'Excessive' FCA Fines Up In The Air
- Settlement Tax Breaks Will Continue Despite JPMorgan Deal
- NJ Senate OKs Bill To Redesignate Medical Marijuana
- NJ High Court Stays Accutane Case, Weighs Judge's Recusal
- Ex-SAC Manager Martoma Was Tossed From Harvard Law
- Fed. Circ. Mulls Rule For Declaratory Judgment Jurisdiction
- Zacadia Overreached In Herbalife $400M Estate, Court Says
- Life Sciences Group Of The Year: Covington & Burling
- DC Circ. Revives K-V's FDA Enforcement Row
- 8th Circ. Affirms Novartis Loss In Aredia, Zometa Suit
- Bard Vaginal Mesh Bellwether Put On Hold
- Female Powerbrokers Q&A: Duane Morris' Sharon Caffrey
- Female Powerbrokers Q&A: Novak Druce's Katy Basile
- Deals Rumor Mill: Novartis, Statoil, Lanco
- McKesson Woos Hedge Fund With Heftier $8.4B Celesio Bid
- GSK Blasts Appeal Bid In Pa. Paxil Venue Dispute
- Forest Lab's Lexapro Causes Fatal Birth Defects, Mom Says
- Teva Says FTC Can't Draw It Into Pay-For-Delay Case
- Steve Cohen Testimony Barred From Martoma Trial
- BioScrip Agrees To Pay $15M In FCA Kickback Suit
- Senators Seek More Clarity On Fed. Agency Settlements
- Laxatives Can Lead To Kidney Injury, Death, FDA Warns
- NuPathe Gets $114M Takeover Bid After Inking Deal With Endo
- Medical Device Co. Found To Infringe Infusion Pump Patent
- FDA Approves Bristol-Myers, AstraZeneca Diabetes Drug
- Pfizer Investors Ask 3rd Circ. To Revive Alzheimer's Drug Row
- Forest Labs Spends $3B For Specialty Pharma Co. Aptalis
- Deals Rumor Mill: McKesson, New York Times, Shell
- Recent Evolutions In The Doctrine Of Patent Exhaustion
- Female Powerbrokers Q&A: Arnstein's Kathleen Gilligan
- Female Powerbrokers Q&A: Faegre Baker's Maureen Maly
- ArthroCare To Pay $30M To End $400M Securities Fraud Probe
- NJ Senate OKs Bill To Require Coverage Of Pain Meds
- FDA Splits Approach To Diabetes Meter Approvals
- NY High Court Mulls Test For Recall-Related Damages
- FTC Halts Supplement Marketers' False Ads, Lax Data Control
- EU Clears Celgene's Abraxane To Treat Pancreatic Cancer
- Duty To Warn Doctrine Weakened For Drugmakers
- Zoll Medical Hits Philips With New Suit In Defibrillator IP War
- J&J Loses Bid To Nix Levaquin Award In 8th Circ.
- Surge Of FDA Activity Caps Quiet Year Of Promo Discipline
- Judge Clears Ex-Ameritox Employee's Jump To Millennium
- Bradley Arant Adds Big Pharma Defense Expert In Miss.
- Female Powerbrokers Q&A: Quarles & Brady's Sarah Coyne
- Female Powerbrokers Q&A: Fox Rothschild's Brett Axelrod
- Bogus Weight Loss Claims Cost Cos. $34M In FTC Settlements
- Novartis Sued Over 'Virus Production' Patent For Flu Shots
- Bankrupt Landauer Gets Nod for $22M Sale To Quadrant
- FDA Floats Plan To Streamline New Drug Trials
- 6 Lessons For Lawyers From Feds' 2013 FCA Haul
- Millennium Labs Says VeriMed Stole Drug Report Name
- Bard Can't Get Memos Excluded From Vaginal Mesh Trial
- Medtronic Pays $160M Cash For Implantable Device Maker
- Boehringer, Teva Sued Again Over Deal To Delay Generic
- 'Datalink' Includes Wireless Tech, Hill-Rom Tells Fed. Circ.
- FTC Hits Maker Of Diet Supplement Products Over Ad Claims
- Deals Rumor Mill: Time Warner, Liberty, KKR
- Enzo Award Raised To $61M In DNA Patent Fight
- Female Powerbrokers Q&A: Ideal Legal Group's Evie Jeang
- Female Powerbrokers Q&A: Akin Gump's Christine LaFollette
- Thermo Fisher Sends $1B In Assets To GE In Deal With EU
- 2013 Provided Few Small-Molecule Decisions
- 7th Circ. Blocks Boehringer Workers' Depos In Pradaxa MDL
- Covington Nabs Ex-Mayer Brown Life Sciences Pro
- Boehringer, Teva Sued Over $120M Pay-For-Delay Deal
- Pa. Appeals Court Favors J&J Unit In Nonsolicitation Spat
- Travelers Told To Hand Heparin Docs To American Capital
- How FDA Would Alter Use Of Antibiotics In Food Animals
- Female Powerbrokers Q&A: Choate's Brenda Jarrell
- Female Powerbrokers Q&A: Bond Schoeneck's Ginny Robbins
- TPG-Backed IMS Seeking $100M In Return To Public Markets
- Novartis Can't Dodge $2.2M Jaw Injury Verdict
- Abbott Settles Stent Kickbacks Case For $5M
- Novartis Jacked Up Painkiller Prices, Class Action Claims
- 3rd Circ. False Ad Ruling No Class Action Killer, Bayer Says
- Dendreon Execs Can't Escape Class Suit Over Stock Sales
- Thompson Stem Cell Patent Appeal Should Be Dismissed
- 2 Traps For Unwary ANDA Filers
- When File Type Matters In E-Discovery
- Roche Ducks FCA Suit Over Nonexistent Lab Tests
- Advanced Cell Agrees To Pay $4M Over Alleged Stock Scheme
- Ameritox Lied About Evidence Destruction, Millennium Says
- Fed. Circ. Finds No Preemption In Eyelash Competition Suit
- Concussion-Injury Supplement Claims Draw FDA's Ire
- PE-Backed Biotech Co. UniQure Eyes $75M IPO
- Pa. Court Voids $28M Verdict Against Zimmer, Marketing Co.
- Defendant In Alleged Drunk Insider Trading Case Settles
- Female Powerbrokers Q&A: Ulmer & Berne's Patty Shlonsky
- Female Powerbrokers Q&A: Fish's Cynthia Walden
- The Year Ahead In Pro Bono
- The Next Supreme Court Cases To Shape Patent Law
- Law360 Names Law Firms Of The Year
- 10 New Year's Resolutions To Boost Firm Gender Diversity
- Law360 Names Practice Groups Of The Year
- Life Sciences Regulation And Legislation To Watch In 2014
- Life Sciences Cases To Watch In 2014